Global Cancer Biomarker Market -2019-2026
|癌症生物標記的全球市場分析 Global Cancer Biomarker Market -2019-2026|
|出版日期: 2020年01月01日||內容資訊: 英文||
本報告提供全球癌症生物標記的市場相關分析，彙整市場基本結構和最新形勢，整體市場趨勢預測 (今後8年份)，各市場區隔 (生物標記/簡介各技術/各用途) 及地區別詳細趨勢，主要的推動及阻礙市場要素，市場佔有率結構，主要企業的簡介等相關調查。
The global cancer biomarker market is estimated to reach a market value of USD XX billion by 2026 from an initial market value of USD 11,479.2 million in 2018. The global cancer biomarker market is forecasted to grow at a CAGR of 6.34% in the forecasted period 2019-2026.
Increasing Incidence and Cancer Prevalent Pool, Growth in Importance of Biological and Targeted Therapies, Increasing Use in Drug Development, increasing strategic alliances between the companies for the development of cancer biomarker, and growing patient awareness campaigns and programs by government, companies, and NGO's are some of the key trends in the cancer biomarker market.
According to Globocan 2012, the incidence rates of cancer types is increasing notably for many cancer types globally. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. Mortality rate of cancers is likely to increase at a higher rate compared to incidence rate during 2015-2030, at a CAGR of 2.6%. By cancer type, incidence population of lung cancer is expected to grow at a faster pace. In terms of mortality too, lung cancers have highest mortality rate, approximately one-fifth of the cancer-related deaths worldwide is due to lung cancers.
Segmentation by Biomarker Type
By biomarker type, genetic biomarker account for the largest share in the cancer biomarker market. The biomarker market is estimated to grow at nominal of pace in the forecasted period growing at a CAGR of XX% in the forecasted period 2019-2026. Genetic Biomarker is defined as a DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention.
Genetic mutations are the primary causes for several cancer types and thus identifying these key mutations holds significant clinical importance in drug development, cancer diagnosis and treatment.
The approval of novel gene based assays and companion diagnostics will fuel the market for genetic biomarkers in the forecast period. For instance, in January 2018, FDA has approved a PMA supplement extending the indications for use of QIAGEN's therascreen EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim's targeted therapy GILOTRIF for first-line treatment of NSCLC.
Segmentation by Geography
North America accounts for the largest market share in the 2017 with the market being dominated by the United States. North America is dominating the cancer biomarkers market due to established R&D infrastructure and high acceptance of biomarker-based cancer testing, adequate reimbursement coverage in this region. In addition, the largest share of North America is due to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, high adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. The US holds the largest market share in North America followed by Canada due to growing research and developments in cancer biomarkers with rising number of cancer cases in this region.
On 5 December 2017, the European Cancer Patient Coalition (ECPC), in collaboration with the Member of the European Parliament Marlene Mizzi (S&D, Malta) organized an event on the topic of Cancer Biomarkers in the Era of Personalized Medicines. The European Medicines Agency has endorsed a UK-US project to use an imaging biomarker to help select Parkinson's disease patients most likely to benefit from clinical trials.
India, China, Brazil, and Australia market are growing at a higher rate while United States, Italy, Germany, Japan, and Spain market are growing at a slower rate but contribute to the largest market revenue in 2017.
The cancer biomarker market is a highly competitive market with genetic biomarker being consolidated market while protein biomarker market being fragmented market. Companies in the industry are focusing on launching novel products into the market with partnerships being the most adopted strategy by the major companies in the industry.
Scope of the Report
Segmentation by Cancer Indication
Segmentation by Biomarker Type
Segmentation by Profiling Technologies
Segmentation by Application
Drug Discovery And Development
Disease Screening and Diagnosis
Treatment Planning & Risk Assessment
The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.